We respond to new research which shows the drug ribociclib reduces the risk of breast cancer recurrence for some women
In response to interim findings from the NATALEE trial presented at ASCO on Friday 2nd June, 2023, Dr Kotryna Temcinaite, head of research communications at Breast Cancer Now, said:
02 Jun 2023
We welcome the SMC's approval of trastuzumab deruxtecan for use on the NHS in Scotland
Responding to the Scottish Medicines Consortium’s (SMC) decision to approve trastuzumab deruxtecan (Enhertu) for use on the NHS in Scotland, Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:
10 Apr 2023
Breast Cancer Now respond to NICE’s decision to approve olaparib for use on the NHS.
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now said:
06 Apr 2023
Breast Cancer Now responds to research about breast cancer risk and hormonal contraceptives
In response to research published in PLOS Medicine looking at breast cancer risk and combined and progestogen-only contraceptives, Dr Kotryna Temcinaite, head of research communications at Breast Cancer Now, said:
22 Mar 2023
We respond to Macmillan Cancer Support's warning of 'perfect storm' of Covid and staff shortages (1)
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
17 Mar 2023
Breast Cancer Now responds to the sad news of Jacqueline Gold's death
Reacting to the sad news of Jacqueline Gold’s death today, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now said:
17 Mar 2023
Breast Cancer Now responds to new research about AI and breast cancer screening
In response to a new trial using AI software within breast cancer screening at Leeds Teaching Hospitals NHS Trust*, Dr Kotryna Temcinaite, head of research communications at Breast Cancer Now, said:
06 Mar 2023
Breast Cancer Now flags concerns over findings of final PAC Report
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
01 Mar 2023
Breast Cancer Now responds to research about detecting breast cancer from fingertip smears
In response to research, published in Scientific Reports*, about detecting breast cancer from fingertip smears, Dr Kotryna Temcinaite, senior research communications manager at Breast Cancer Now, said:
20 Feb 2023
Breast Cancer Now responds to Cancer Research UK’s estimate that the number of people diagnosed with cancer will ‘rise by a third by 2040’
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
03 Feb 2023
We respond to the launch of the first UK proton beam therapy trial for breast cancer patients
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
03 Jan 2023
We respond to new estimates that 57,215 people were living with secondary (metastatic) breast cancer in England in 2020 to 2021
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, has commented on the new estimates.
22 Dec 2022